IL17A and psoriasis vulgaris: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits IL‐17A and IL‐17F and was approved by National Institute for Health and Care Excellence in September 2021 for treating adults with moderate to severe plaque psoriasis after standard therapy was unsuccessful or not tolerated.